Investments · Synthetic biology
SoftBank Vision Fund leads $400 million round in microbe engineering firm Zymergen
- Investor
- SoftBank Group (via SoftBank Vision Fund) (Tokyo)
- In
- Zymergen, Emeryville, California
- Value
- More than $400M Series C
- Status
- Completed in December 2018.
- Date
- 2018-12-13
SoftBank Group's Vision Fund led a Series C round of more than $400 million in Zymergen, an Emeryville, California company that engineers microbes to make chemicals and materials.
Why it matters
The round extended the Vision Fund's portfolio into biotechnology for industrial materials.
Sources
Kakehashi M&A News home
